Compare KraneShares Electric Vehicles and Future Mobility (KARS) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
KraneShares Electric Vehicles and Future Mobility vs Zimmer Biomet Holdings Inc — how do they compare? KraneShares Electric Vehicles and Future Mobility trades at $30.53, while Zimmer Biomet Holdings Inc trades at $97.03 (market cap $18.65B). The key difference: Zimmer Biomet Holdings Inc pays a 0.98% dividend while KraneShares Electric Vehicles and Future Mobility pays none, and Zimmer Biomet Holdings Inc is trading nearer its 52-week high, KraneShares Electric Vehicles and Future Mobility nearer its low. Which is the better fit depends on your goals.
| KARS | ZBH | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $38.01 | $107.71 |
52-Week Low | $25.59 | $79.58 |
Market Cap | — | $18.65B |
Enterprise Value | — | $25.72B |
Dividend Yield | — | 0.98% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
KARS trades at $30.86, up 2.51% today, with a bullish technical signal but bearish moving averages. Recent news highlights global EV sales growth, particularly in Europe and China, though U.S. adoption lags. The stock shows strong momentum with RSI_6 at 80.23 indicating overbought conditions, while support and resistance cluster around $30-$31.
The outlook for KARS is mixed; positive EV industry trends support growth, but high RSI suggests near-term pullback risk. Investment opportunity lies in global EV expansion, while risks include U.S. market hesitation and competitive pressures from Chinese automakers.
Zimmer Biomet (ZBH) trades at $96.55, down 0.66% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $103.56. The company reported strong Q2 2026 earnings, beating estimates with EPS of $2.07, and raised its full-year outlook. Revenue growth remains steady, supported by hips, specialty businesses, and technology, though net income margin has moderated from 2023 peaks. Recent corporate news includes a dividend declaration and expansion of its technology center in India.
The outlook for ZBH is positive, driven by consistent earnings beats and strategic growth initiatives, but investors face risks from margin pressure and increasing debt levels. The stock offers potential upside to the consensus target, supported by institutional accumulation, though competitive and macroeconomic headwinds in the medtech sector warrant caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About KraneShares Electric Vehicles and Future Mobility
KARS invests in the global electric vehicle ecosystem and future mobility. It tracks the Bloomberg Electric Vehicles Index, providing exposure to EV manufacturers, battery technology, and lithium miners like Tesla, BYD, and Albemarle.
Read more on KARS →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
